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E 
Abstract The regulation of apolipoprotein A-I (apo A-l) gene 
expression by 12-O-tetradecanoylphorbol 13-acetate (TPA) was 
in~ estigated in the human hepatoma cell line Hep G2. TPA treat- 
ment decreased apo A-I mRNA levels in a time-dependent man- 
ner, by up to 50% versus control cells within 24 h. Nuclear run-on 
transcription assays demonstrated a transcriptional effect of 
TPA. Using transfection analysis with a plasmid construct con- 
taining the -1378/+11 apo A-I promoter fused to the secreted 
placental alkaline phosphatase (SPAP) reporter gene, we showed 
that the SPAP activity was decreased to 50% when Hep G2 cells 
were incubated in the presence of TPA. The inhibitory effect of 
TPA was still maintained when fragment - 253 to - 4 of apo A-I 
promoter was linked to the CAT reporter gene. These data indi- 
cate that transcriptional modulation of apolipoprotein A-I gene 
expression following phorbol ester treatment is transduced by 
gene elements located between -253 and -4  of the apo A-I 
promoter. 
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1. Introduction 
Apolipoprotein A-I (Apo A-I) is the major protein compo- 
nent of high density lipoprotein [1] and is synthesized in the 
li~ er and intestine [2]. Apo A-I has several roles in lipoprotein 
m~tabolism. It acts as a cofactor for catalytic onversion of 
cholesterol into cholesterol ester by the action of lecithin- 
cl~olesterol acyl transferase (LCAT) [3] and has been linked to 
rcverse cholesterol transport [4,5]. Lipid transport ismodulated 
b', an altered level of apoliproteins, in response to physiological 
c~nditions [6,7]. Some of the regulation ismediated via apolipo- 
p~ otein gene expression. Several studies have shown that the 
alaount of apo A-I mRNA in the liver is controlled by hormo- 
n~d and nutritional factors [8-10] and is developmentally regu- 
lated [11]. Human subjects with genetically determined low or 
h~,gh plasma apo AI or high density lipoprotein levels have an 
i~creased or decreased risk of developing atherosclerosis [12], 
respectively, indicating the importance of regulation of apo A-I 
s.x nthesis. 
Phorbol esters have been shown to induce several changes in 
lipoprotein metabolism, including changes in the LDL-receptor 
mediated uptake and lipoprotein lipase activity [13,14]. How- 
ever, much less is known about the molecular mechanism by 
which phorbol ester modulates apolipoprotein gene expression. 
In a recent study, it was shown that apo C-Il l  gene transcrip- 
tion was regulated by a TPA-inducible activity mediated by 
NFxB binding sites [15]. In another study, it was shown that 
transcriptional ctivation of the apo E gene during TPA-in- 
duced macrophage differentiation was associated with induc- 
tion of AP-l-like proteins [16]. The promoter regions of several 
inducible genes share a conserved 8 bp motif which is known 
to bind the AP-1 transcription complex [17]. This complex 
includes the transcriptional ctivator proteins c-fos and c-jun 
which are induced by the activation of protein kinase C [18]. 
Additionally, for a number of genes, enhanced gene expression 
after TPA stimulation has also been shown to be transduced 
by AP-2 and NFxB binding sites [19,20]. In this paper, we 
investigate the effect of TPA on apo A-I gene expression i  the 
Hep G2 cell line. This cell line is well characterized and has been 
used extensively as a model to study hepatic lipoprotein metab- 
olism and apolipoprotein gene expression [8,21-22]. We pro- 
vide evidence that TPA exerts a negative ffect on apo A-I gene 
expression at the transcriptional level in Hep G2 cells and that 
this effect is mediated by element(s) located between -253 to 
-4  in the Y-flanking region of the apo A-I gene. 
2. Materials and methods 
2.1. Materials 
Dulbecco's modified Eagle's medium (DMEM), L-glutamine, antibi- 
otics, fetal calf serum (FCS) and Dulbecco's phosphate-buffered saline 
(PBS) were obtained from Gibco-BRL (European division). [~4C]chlor- 
amphenicol, [~-32PJdCTP, [T-32P]ATP, [~-32p]UTP, Nylon Hybond N ÷, 
Royal X-Omat films and multi-primer kits were purchased from Amer- 
sham International. We obtained fl-galactosidase expression vector 
pCHll0 from Pharrnacia. All other products were purchased from 
Sigma. 
2.2. Cell culture 
Hep G2 cells were cultured at 37°C in a humidified atmosphere of 
5% CO2, 95% air. Hep G2 cells were grown in DMEM containing 10% 
fetal calf serum (FCS), 2 mM e-glutamine and antibiotics (penicillin, 
streptomycin). 24 h prior to TPA treatment, when Hep G2 cells were 
confluent, he cells were washed twice with PBS (pH 7.4) and further 
maintained DMEM medium without FCS. 
*~ ~orresponding author. Fax: (33) (19 1) 40 01 14 95. 
A,breviations: apo, apolipoprotein; CAT, chloramphenicol acetyl 
transferase; FCS, fetal calf serum; PBS, phosphate-buffered saline; 
SPAP, secreted placental phosphatase alcaline; TPA, 12-O-tetrade- 
canoylphorbol 13-acetate. 
2.3. RNA extraction and analysis 
After extraction by the method of Chomczynski and Sacchi [23], total 
RNA (10/2g) was analyzed by Northern-blot as previously described 
[8]. The blots were hybridized with apo A-I cDNA probe labeled with 
[~-32p]dCTP by random priming and rehybridized to a 28S rRNA probe 
labeled with T4 polynucleotide kinase and [T-32P]ATP. The apo A-I 
mRNA signal was quantified by densitometric scanning and was 
0o14-5793/95l$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
S SDI  0014-5793(95)01252-4 
100 Y Vandenbrouck et al . /FEBS Letters 376 (1995) 99-102 
A. 
loo 
"~ 50 / 
li 25 
4 
/ 
9 15 20 24 
Time of TPA treatment (Hr) 
B. 
control TPA I II I 
~ - -  2SS 
--  Apo AI 
Fig. 1. Time course of TPA effect on apo A-l mRNA level in Hep G2 
cells. Hep G2 cells were maintained for 24 h in serum-free medium and 
were then treated with 100 nM TPA. Total RNA was extracted at the 
time indicated and analyzed by Northern blotting as described in sec- 
tion 2. (A) Data obtained by densitometric s anning were corrected for 
differences in RNA loading by using the 28S rRNA signal. Data are 
expressed as the percentage of the apo A-I signal from control cells. 
Each value is the mean + S.E.M. of data collected from three independ- 
ent experiments. (B) Representative autoradiogram of Northern-blot 
performed on Hep G2 cells 24 h after 100 nM TPA treatment. 
described [25]. Secreted placental alkaline phosphatase (SPAP) was 
assayed on the day following transfection, Hep G2 cells were trypsi- 
nized, seeded on microwell plates (microdish well-plate 96F). SPAP 
activity was measured in FCS-free DMEM without phenol red as fol- 
lows; the reaction was started by incubating 100/11 of medium with 150 
/zl ofp-nitrophenyl phosphate substrate 1X on a microplate at 37°C for 
1 h and stopped by adding 2M NaOH. Absorbance of each microwell 
plates was determined at 405 nm using a Dynatec MR5000 microplate 
reader. For total cellular protein determination, cells were washed once 
in PBS, then fixed by ethanol for 15 min, ethanol was removed and 
0.25% Bengal pink was added for 15 rain. Microplates were rinsed, 
dried, eluted with 0.2 M NaOH/DMSO (v/v) and the absorbance was 
determined at 550 nm using the microplate reader. 
3. Results and discussion 
Apo AI gene expression has been shown to be regulated by 
diets and thyroid hormone at a post-transcriptional level [8,9]. 
Nothing is known about  a putative transcriptional regulation 
of the apo AI gene. Furthermore,  the transduction pathways 
leading to apo AI gene expression in response to extracellular 
signals have not been elucidated. In this paper, we have demon- 
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Fig. 2. Relationship between the presence of Pbu2 and the reduction 
ofapo AI mRNA. Cells were incubated with 500 nM PBu 2 for 24 h and 
then washed three times with DMEM medium, and incubated for 24 h. 
PBu 2 (500 nM) was added again and cells were reincubated for 24 h. 
The apo AI mRNA level was normalized to the value of control cell, 
which was given the arbitrary value of 100. Data represent he 
mean + S.D. from three independent experiments. 
corrected for differences in RNA loading by comparison with the sig- 
nals generated by the 28S rRNA. 
2.4. Nuclei isolation and run-on assays 
The rate of apo A-I gene transcription was measured by a run-on 
assay 24 h after TPA treatment. Nuclear isolation and hybridization of 
nuclear transcripts o immobilized DNA were performed as previously 
described [8]. 
2.5. Plasmids, cell transfections, alkaline phosphatase and CAT assays 
The plasmid pA-I-SPAP containing the - 1378l+ 11 region of the 
human apo A-I gene cloned upstream the secreted placental alkaline 
phosphatase (SPAP) gene was generously donated by Glaxo-France 
(Les Ulis) and the plasmid pEMBL-8-CAT containing the human apo 
A-I promoter sequence -253l -4  was generously donated by Dr. Zan- 
nis [24]. Transient transfections of Hep G2 cells were performed by the 
calcium phosphate co-precipitation method. Chloramphenicol acetyl 
transferase (CAT) activity was determined by acetylation of [14C]chlor- 
amphenicol followed by thin layer chromatography as previously 
A. 
Apo AI 
GAPDH 
pUCI9  I 
CONTROL TPA 
B. 
.2 
g~ 
.¢ 
O g~ 
.¢ 
0.5 
~ m  
CONTROL TPA 
Fig. 3. Nuclear un-on analysis of apo A-I gene transcription after TPA 
treatment. After 24 h of TPA (100 nM) treatment, nuclei from control 
and treated Hep G2 cells were isolated and transcription run-on assays 
were performed as described in section 2. Equal amounts (50" 106 cpm) 
of 32p-labeled RNA were hybridized to nitrocellulose filters containing 
10/zg of linearized plasmids bearing apo A-I, GAPDH cDNA se- 
quences and pUC19 as a background control: (A) Representative au- 
toradiogram of run-on assays performed on Hep G2 cells after 24 h 
incubation with (right panel) or without 100 nM TPA (left panel). 
(B) The amount of each band was analyzed using a videocopy/Densylab 
system from Bioprobe and the data shown are the results of the apo 
A-I/GAPDH ratio after subtraction of background radioactivity hy- 
bridized to pUC19. The control value is arbitrarily designated as 1. 
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strated for the first time the inhibition of apo AI gene expres- 
sion by phorbol esters which stimulate protein kinase C. 
By Northern blot analysis, we examined the apo A-! mRNA 
lmels in Hep G2 cells incubated with 100 nM TPA for various 
times (Fig. 1A). Data from scanning densitometry showed that 
TPA had no effect on apo A-I mRNA level before 15 h of 
trt atment, at which time a significant 25% decrease compared 
to the control value was observed. At 24 h of TPA treatment, 
ap~ A-I mRNA level decreased to50% compared to the control 
(F g. 1B). The effect of TPA on apo A-I mRNA level was 
mtximal at 24 h and was still observed at 48 h (not shown). In 
order to investigate he reversibility of this effect, Hep G2 cells 
w~ re incubated in the presence of phorbol ester 12-13 dibu- 
ty~ate (PBu2) which is rapidly released from its receptor after 
w shing [26]. A 24 h incubation i  the presence of PBu2 also 
re,luced the apo AI mRNA level (Fig. 2), After washing and 
incubation for 24 h, the apo AI mRNA level was restored to 
th.: control value. Renewed PBu 2 treatment then decreased the 
aFo AI mRNA level. The relatively long lag period and slow 
in!libition kinetics of apo A-I by TPA suggest the involvement 
ol a long- lived protein intermediate, assuggested in other cell 
s5 ~tems [27]. In order to determine whether the changes in the 
st:ady- state level of apo A-I mRNA were due to changes in 
th ~ rate of transcription i itiation or elongation, run-on assays 
w,~re performed on Hep G2 cells using nuclei from either con- 
tr,)l cells or cells treated with TPA for 24 h. Quantification of
tt z autoradiographic data (Fig. 3A) by scanning densitometry 
al~er correction for glyceraldehyde-3-phosphate dehydroge- 
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!~ g. 4. Time course of TPA action on SPAP activity in Hep G2 cells 
t~ ~msfected with apo A-I promoter (- 1378/+ 1I)-SPAP reporter gene 
c, instruct. Hep G2 cells transiently transfected with the apo A-I (- 1378/ 
13)-SPAP construct were trypsinized and seeded in microwell plate. 
I ae following day, cells were placed in serum-free medium for 24 h and 
I PA (100 nM) was added for the times indicated. SPAP activity was 
determined asdescribed insection 2and expressed in relation to total 
cellular protein content. ~, control cells; m, TPA-treated cells. Data 
represent mean + S.D. from three xperiments performed inquadripli- 
cate. 
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Fig. 5. Effect of TPA on CAT activity in Hep G2 cells transfected with 
apo A-I promoter (-255/-5)-CAT reporter gene construct. Hep G2 
cells transiently transfected with the apo A-I (- 253/- 4)-CAT construct 
were grown in serum-free medium for 24 h and treated with or without 
100 nM TPA for 24 h. (A) Autoradiogram representing chlorampheni- 
col acetyl transferase (CAT) assays performed in transfected Hep G2 
cells. (B) CAT activity was measured as described in section 2 and 
normalized to the fl-galactosidase activity to correct for differences in 
transfection efficiency. Data represent mean + S.D. from three separate 
experiments performed in triplicate. 2AC: 2-acetyl chloramphenicol. 
3AC: 3-acetyl chloramphenicol. 
nase (GAPDH) gene transcription showed that the apo A-I 
transcription rate was reduced by one half at 24 h (Fig. 3B). 
These results therefore indicate that the maximum 2-fold de- 
crease in the rate of apo A-I gene transcription could fully 
account for the changes in the steady-state l vel of apo A-I 
mRNA. 
We then investigated the region of the apo A-I gene which 
responds to TPA by first transfecting Hep G2 cells with the 
plasmid pA-I-SPAP which contains the - 1378 to + 11 fragment 
of the apo A-I promoter fused to the secreted placental alkaline 
phosphatase (SPAP) reporter gene. Results in Fig. 4 show the 
absence of any detectable effect of TPA before 9 h of treatment, 
at which time a slight decrease of SPAP activity of about 15% 
was observed compared to control cells. At 24 h of TPA treat- 
ment, SPAP activity was decreased by 50% of control values, 
indicating that complete TPA responsiveness was mediated by 
the - 1378 to + 11 fragment of the apo A-I promoter. To more 
precisely delineate the apo A-I promoter egion involved in 
TPA-responsiveness, we transfected Hep G2 cells with the plas- 
mid pEMBL8-CAT which contains the CAT reporter gene 
under the control of the -253 to -4  region of the apo A-I gene 
promoter. Results in Fig. 5 show that CAT activity was de- 
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creased by one half after 24 h of TPA treatment, indicating that 
TPA-responsive elements were located in the proximal apo A-I 
gene promoter. 
It can be concluded from these data that the nucleotides in 
the apo A-I promoter responsible for partial inhibition of tran- 
scription by TPA are located within the 249 bp segment of 
DNA between positions -253/ -4.  The negative ffect appears 
to involve an interaction between a cis-regulatory element and 
a trans-acting factor(s) whose activity is regulated by TPA- 
triggered phosphorylation. It is now well established, for a 
number of regulatory systems, that gene transcriptional re- 
sponses to TPA can be transduced by AP-1, AP-2 or NFxB 
binding sites [17-20]. Inspection of the sequence of the human 
apo A-I gene promoter [28] between position -253/ -4 ,  5' to 
the transcription start site revealed a single potential NFxB 
binding site located at -22, and two CCCGCCCC and 
CCCTGCCC motifs located at -228 and -199, respectively, 
which closely resemble the AP-2 elements [29]. Involvement of 
AP-2 in TPA-mediated responsiveness can be excluded, since 
Hep G2 lacks endogenous AP-2 mRNA and protein [30]. Apo 
A-I gene expression could therefore be modulated by an NFxB 
regulatory element, as previously observed for the apo C-III 
gene promoter [15]. However, although a perfect AP-1 binding 
site [29] has not been found in the apo A-I promoter, the AP-1 
transcription complex may be involved in the effect of TPA via 
another cis-regulatory element, as demonstrated for other 
genes [31]. Footprinting and gel-retardation analysis should 
identify the specific DNA sequence(s) and facilitate characteri- 
zation of the regulatory protein(s) responsible for the effect of 
TPA on apo A-I gene transcription. 
As shown for apolipoproteins E and CIII [15,16], this study 
demonstrates that TPA modulates apo A-I gene expression at 
the transcriptional level in the Hep G2 cell line. TPA treatment 
results in partial inhibition of apo A-I gene transcription and 
this effect is mediated by elements located in the 5'-flanking 
region of the apo A-I gene between ucleotides -253 to -4  
upstream of the transcription start site. To our knowledge, our 
report is the first demonstration f regulatory elements within 
the apo A-I gene that respond to extracellular signals. 
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